Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A framework for setting enrollment goals to ensure participant diversity in sponsored clinical trials in the United States.

Autor: Cullen MR; Department of Medicine, Biomedical Data Science and Health Policy, Stanford University, Stanford, CA, USA., Lemeshow AR; Pfizer Inc., NY, USA., Amaro S; Pfizer Inc., NY, USA., Bandera EV; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Cooper LA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kawachi I; Department of Social Epidemiology, Harvard University, Cambridge, MA, USA., Lunyera J; Division of General Internal Medicine, Department of Medicine, Duke University, Durham, NC, USA., McKinley L; Pfizer Inc., NY, USA., Poss CS; Pfizer Inc., NY, USA., Rottas MM; Pfizer Inc., NY, USA., Schachterle SE; Pfizer Inc., NY, USA., Thadeio PF; Pfizer Inc., NY, USA., Russo LJ; Pfizer Inc., NY, USA. Electronic address: leo.j.russo@pfizer.com.

Publikováno v: Contemporary clinical trials [Contemp Clin Trials] 2023 Jun; Vol. 129, pp. 107184. Date of Electronic Publication: 2023 Apr 11.

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Autor: Brown MF; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. matthew.f.brown@pfizer.com, Bahnck KB, Blumberg LC, Brissette WH, Burrell SA, Driscoll JP, Fedeles F, Fisher MB, Foti RS, Gladue RP, Guzman-Martinez A, Hayward MM, Lira PD, Lillie BM, Lu Y, Lundquist GD, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Roache JH, Shavnya A, Shepard RM, Trevena KA, Tylaska LA

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2007 Jun 01; Vol. 17 (11), pp. 3109-12. Date of Electronic Publication: 2007 Mar 15.